Who executed the Maze Therapeutics (MAZE) share sales disclosed for Jason Coloma?

The sales were executed by the Coloma Family Trust and The Coloma 2021 Irrevocable Trust . Jason Coloma and his spouse serve as co-trustees of these trusts, so the holdings and transactions are reported as indirect ownership on the Form 4.

Maze Therapeutics (MAZE) CEO’s family trusts sell 34,501 shares under 10b5-1 plan

Q: What insider transactions did Maze Therapeutics (MAZE) report in this Form 4?

The Form 4 reports indirect open-market sales of 34,501 Maze Therapeutics shares linked to CEO Jason V. Coloma. The sales were executed by family trusts on July 1, 2026 , at weighted average prices around $30 per share.

Q: How many Maze Therapeutics (MAZE) shares were sold and at what prices?

A total of 34,501 shares of Maze Therapeutics common stock were sold. Weighted average prices were $30.4359, $29.9535, and $29.9754 per share, with underlying trade ranges between about $29.37 and $30.49 per share.

Q: What do the weighted average prices on the Maze Therapeutics (MAZE) Form 4 mean?

The reported prices are weighted averages of multiple trades. Footnotes explain each batch of shares was sold in several transactions within stated price ranges, such as $29.375 to $30.37, with full trade-by-trade details available upon request.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Maze Therapeutics, Inc. director and Chief Executive Officer Jason V. Coloma reported indirect open-market sales of common stock totaling 34,501 shares on July 1, 2026, executed by family trusts.

The Coloma Family Trust sold 1,597 shares at a weighted average of $30.4359 per share and 30,311 shares at a weighted average of $29.9535 per share. The Coloma 2021 Irrevocable Trust sold 2,593 shares at a weighted average of $29.9754 per share. According to a footnote, these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026, indicating they were scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 34,501 shares ($1,034,253)

Net Sell 3 txns

Insider Coloma Jason V

Role Chief Executive Officer

Sold 34,501 shs ($1.03M)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,593	$29.9754	$78K
Sale	Common Stock	30,311	$29.9535	$908K
Sale	Common Stock	1,597	$30.4359	$49K

Holdings After Transaction: Common Stock — 23,337 shares (Indirect, The Coloma 2021 Irrevocable Trust)

Footnotes (1)

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.455 to $30.38 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 4 and 6 of this Form 4. These securities are directly held by The Coloma 2021 Irrevocable Trust (the "Irrevocable Trust"), for which the reporting person and his spouse serve as co-trustees. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.375 to $30.37 per share, inclusive. These securities are directly held by the Coloma Family Trust (the "Family Trust"), for which the reporting person and his spouse serve as co-trustees. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.385 to $30.49 per share, inclusive.

Key Figures

Total shares sold: 34,501 shares First block weighted average price: $30.4359/share Second block weighted average price: $29.9535/share +5 more

8 metrics

Total shares sold 34,501 shares Net insider sales on July 1, 2026

First block weighted average price $30.4359/share 1,597 shares sold by Coloma Family Trust

Second block weighted average price $29.9535/share 30,311 shares sold by Coloma Family Trust

Third block weighted average price $29.9754/share 2,593 shares sold by Coloma 2021 Irrevocable Trust

Shares remaining in family trust (example) 288,768 shares Coloma Family Trust holdings after one transaction

Shares remaining in irrevocable trust 23,337 shares The Coloma 2021 Irrevocable Trust after sale

Trading plan adoption date February 6, 2026 Rule 10b5-1 plan governing reported sales

Net buy/sell direction -34,501 shares Net-sell across reported transactions

Key Terms

Rule 10b5-1 trading plan, weighted average price, Irrevocable Trust, Family Trust, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The reported price in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Irrevocable Trust financial

"These securities are directly held by The Coloma 2021 Irrevocable Trust"

An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

Family Trust financial

"These securities are directly held by the Coloma Family Trust"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:29 PM Accepted by SEC EDGAR 07/02/2026 - 04:28 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coloma Jason V

(Last)

(First)

(Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/01/2026		S⁽¹⁾		2,593	D	$29.9754⁽²⁾	23,337	I	The Coloma 2021 Irrevocable Trust⁽³⁾
Common Stock	07/01/2026		S⁽¹⁾		30,311	D	$29.9535⁽⁴⁾	288,768	I	Coloma Family Trust⁽⁵⁾
Common Stock	07/01/2026		S⁽¹⁾		1,597	D	$30.4359⁽⁶⁾	287,171	I	Coloma Family Trust⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.455 to $30.38 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 4 and 6 of this Form 4.

3. These securities are directly held by The Coloma 2021 Irrevocable Trust (the "Irrevocable Trust"), for which the reporting person and his spouse serve as co-trustees.

4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.375 to $30.37 per share, inclusive.

5. These securities are directly held by the Coloma Family Trust (the "Family Trust"), for which the reporting person and his spouse serve as co-trustees.

6. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.385 to $30.49 per share, inclusive.

	/s/ Courtney Phillips, as attorney-in-fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Maze Therapeutics (MAZE) report in this Form 4?

The Form 4 reports indirect open-market sales of 34,501 Maze Therapeutics shares linked to CEO Jason V. Coloma. The sales were executed by family trusts on July 1, 2026, at weighted average prices around $30 per share.

How many Maze Therapeutics (MAZE) shares were sold and at what prices?

A total of 34,501 shares of Maze Therapeutics common stock were sold. Weighted average prices were $30.4359, $29.9535, and $29.9754 per share, with underlying trade ranges between about $29.37 and $30.49 per share.

Were Jason Coloma’s Maze Therapeutics (MAZE) stock sales pre-planned under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were effected under a Rule 10b5-1 trading plan adopted on February 6, 2026. Such plans schedule trades in advance, reducing the significance of trade timing as a signal of management’s short-term outlook.

Does the Form 4 show Jason Coloma still holding Maze Therapeutics (MAZE) shares after the sales?

Yes. After the July 1, 2026 sales, the Form 4 shows the trusts still holding indirect positions, including 287,171 shares following one transaction and 288,768 shares following another, plus 23,337 shares in the irrevocable trust, indicating substantial remaining ownership.

What do the weighted average prices on the Maze Therapeutics (MAZE) Form 4 mean?

The reported prices are weighted averages of multiple trades. Footnotes explain each batch of shares was sold in several transactions within stated price ranges, such as $29.375 to $30.37, with full trade-by-trade details available upon request.